Yes, you need a diagnosis of moderate to severe Alzheimer's disease or dementia to be prescribed memantine (Namenda).
Memantine is FDA-approved specifically for moderate to severe dementia of the Alzheimer's type, and should only be prescribed when you have an established diagnosis of dementia in this severity range 1. This is not a medication for memory concerns, mild cognitive impairment, or prevention in people without dementia.
Who Can Be Prescribed Memantine
FDA-Approved Indication
The FDA label is clear: memantine is indicated exclusively for moderate to severe dementia of the Alzheimer's type 1. The clinical trials that established its efficacy enrolled patients with:
- Mini-Mental State Examination (MMSE) scores between 3-14
- Global Deterioration Scale stages 5-6
- Diagnosed by DSM-IV and NINCDS-ADRDA criteria 1
Evidence-Based Recommendations by Severity
For Moderate-to-Severe Alzheimer's Disease:
- Strong recommendation to use memantine - High-quality evidence shows small but consistent clinical benefits in cognition (3.11 points on SIB), activities of daily living (1.09 points on ADL19), behavior (1.84 points on NPI), and global function (0.21 points on CIBIC+) 2, 3
- Works whether or not you're already taking cholinesterase inhibitors 4, 2
For Mild Alzheimer's Disease (MMSE 20-23):
- Not recommended - Evidence shows memantine probably provides no benefit in mild AD for cognition, daily function, or behavior 2
- May actually increase treatment discontinuation due to adverse events (RR 2.12) 2
- Despite being used off-label in the USA for mild AD, the evidence does not support this practice 2
For Vascular Dementia:
- Memantine may provide small benefits in mild-to-moderate vascular dementia for cognition and behavior, though evidence is more limited 4, 2
Common Pitfalls to Avoid
Do not prescribe memantine for "prevention" - While there is an ongoing feasibility trial exploring prevention in at-risk individuals 5, this is investigational only and not supported by current evidence
Do not use in mild cognitive impairment or subjective memory complaints - These are not dementia diagnoses and memantine has no established role here
Severity matters - The clinical practice guidelines emphasize that cholinesterase inhibitors are approved for mild-to-moderate dementia, while memantine is specifically for moderate-to-severe disease 4
The Bottom Line
You must have a formal diagnosis of dementia—specifically moderate to severe Alzheimer's disease—to appropriately receive memantine. The diagnosis should be established through clinical criteria (DSM-IV, NINCDS-ADRDA) with cognitive testing confirming moderate-to-severe impairment 1. Using memantine without this diagnosis, particularly in mild disease or for prevention, lacks evidence support and may expose you to unnecessary adverse effects without benefit 2.